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Abstract
Here, we investigate induction of immunological tolerance by lentiviral based gene therapy
in a mouse model of rheumatoid arthritis, collagen II-induced arthritis (CIA). Targeting the
expression of the collagen type II (CII) to antigen presenting cells (APCs) induced antigen-
specific tolerance, where only 5% of the mice developed arthritis as compared with 95% of
the control mice. In the CII-tolerized mice, the proportion of Tregs as well as mRNA expres-
sion of SOCS1 (suppressors of cytokine signaling 1) increased at day 3 after CII immuniza-
tion. Transfer of B cells or non-B cell APC, as well as T cells, from tolerized to naïve mice all
mediated a certain degree of tolerance. Thus, sustainable tolerance is established very
early during the course of arthritis and is mediated by both B and non-B cells as APCs. This
novel approach for inducing tolerance to disease specific antigens can be used for studying
tolerance mechanisms, not only in CIA but also in other autoimmune diseases.
Introduction
The main feature of rheumatoid arthritis (RA) is loss of tolerance to self-antigens followed by
inflammation and joint destruction. Immunosuppressive drugs reduce the immune response
to self-antigens but unfortunately they also increase the risk for infections [1]. An ideal way to
treat RA would be to re-establish tolerance without a general suppression of the immune sys-
tem. However, therapeutic tolerance has not yet been achieved in clinical trials [2], largely
because the tolerogenic mechanisms are poorly understood.
The most commonly used mouse model for RA is collagen type II (CII)-induced arthritis
(CIA). CII-specific tolerance in CIA depends on presentation of an already identified CII-pep-
tide (amino acids (aa) 259–270) [3] in complex with the major histocompatibility complex
type II (MHCII) Aq molecule [4,5]. To study tolerance mechanisms, the CII protein or CII-
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peptides in their native or modified forms have been administered via various routes and at dif-
ferent time points before induction or during the course of CIA: e.g. orally [6–8] intravenously
[9], intraperitoneally [10] or nasally [11,12]. It has become apparent that the glycosylation pat-
tern of CII is of major importance for tolerance induction in CIA [13,14], and that also trun-
cated forms of the CII-peptide [15] can induce tolerance in mice provided that they still bind
to the Aq molecule. These and other studies have provided invaluable data, but they have also
highlighted at least two complications in tolerance induction. First, the tolerogen can also trig-
ger a pathogenic immune activation under circumstances when the tolerogen has adjuvant
properties, a risk that is increased if proteins are administered exogenously [16]. Second, the
half life of the tolerogen is too short to be effective, e.g. when administered as peptides [17],
and thereby only presented to the immune system at delivery time points. However, the mech-
anisms maintaining tolerance vary during the course of CIA and thus, even if tolerization time
points prior CII-immunization are fine-tuned, a system that targets antigen presenting cells
(APCs) and allows continuous expression of a tolerogenic CII-epitope is lacking.
Tolerance is not due to lack of immune stimulation but rather an active immune regulation
that involves several different cell types. Adoptive transfer of CII-pulsed dendritic cells (DCs)
[18,19] or indoleamine 2,3-dioxygenase (IDO) expressing [20,21] DCs from either orally CII
tolerized mice or in vitromanipulated DCs have been found to alleviate, but not abrogate
arthritis development. The effect seemed mainly to be attributed to induced Foxp3+ regulatory
T cells (Tregs). Further supporting a role for Tregs in tolerance to CIA, another study showed a
significant increase in the number of Tregs in CII tolerized mice [22]. B cells and CII-specific
autoantibodies are hallmarks in CIA, and in the great majority of tolerance studies CII-specific
antibodies decrease. However, not only the CII-specific antibodies, but also the B cells them-
selves are important in CIA, as B cell depletion delays the onset of arthritis [23]. B cells also
seem to take an active part in tolerance induction since presentation of self-antigen by B cells
results in Treg induction rather than in anergy or clonal deletion [24]. Also B regulatory cells
are of importance for regulation of the joint specific immune response and development of
CIA [25–28].
The suppressors of cytokine signaling (SOCS) protein family, which are induced by various
cytokines, e.g. IL-10 [29] are important regulators of immune responses. The SOCS proteins
exert their functions through negative feedback on the JAK/STAT pathway [30,31]. SOCS
have been strongly implicated in regulation of autoimmune conditions, e.g. enhanced SOCS1
expression in NZB/Wmice correlated with reduced IFN- γ production and restored the
IFN-γ signaling pathway [32]. Further, up-regulation of SOCS1 and/or 3 in CIA coincided
with increased IL-10 production and reduced severity of arthritis [33,34]. These effects are
partly due to the importance of SOCS proteins in sustaining the regulatory phenotype of
FoxP3+ cells and to create a tolerogenic cytokine milieu that prevents autoimmune reactions
[35,36].
We have previously shown an induction of partial tolerance in CIA upon intravenous injec-
tion of lentiviral particles that code for the expression of the CII-peptide aa259-270 on MHCII
in a fraction of host cells [37,38]. We hypothesize that a further increased expression of the tol-
erogen would induce complete CII-specific tolerance in CIA and allow detailed studies of
immunological mechanisms. To this end we developed a mouse model using lentiviral based
gene therapy in which the tolerogen is permanently expressed on MHCII Aq already before
CIA is induced. In this model an almost complete and sustainable tolerance to CIA is estab-
lished very early after immunization and shows the immunological complexity of tolerance
and allows for further mechanistic studies in the field.
Antigen-Specific Tolerance in Arthritis
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Generation of the CII expressing lentiviral vector (LNT-CII) has been described previously
[37] (Fig 1A). Briefly, CII aa259–270 or CLIP amino acids were cloned into the class II–associ-
ated invariant chain peptide position of the invariant chain (Ii) to achieve efficient loading of
and binding to MHCII. Next, the generated Ii-fragments were subcloned into the lentiviral vec-
tor pHR’SIN-cPPT-SFFV and named; LNT-CII and LNT-Ctrl. SFFV was used as a general pro-
moter that ensures a high expression in all cell types.
Production of lentiviral particles
Vesicular stomatitis virus—G pseudotyped lentivirus was produced by transient transfection of
293FT cells with three plasmids; the self inactivating transfer vector plasmid LNT-CII or
LNT-Ctrl, the multi-deleted packaging plasmid; pCMVΔR8.74 and the VSV-G envelope;
pMD.G2 and titrated as previously described [38]
Mice
Male DBA/1 mice 6–8 weeks old were obtained from Taconic (Europe A/S, Ry, Denmark) and
housed in a pathogen-free barrier facility (12-hr light/12-hr dark cycle) and fed water and
rodent chow. The chow was placed on the cage floor and the water bottle tip was reachable
when the mice stood on four paws. All mice were monitored daily. All animal studies were
approved by the local Animal Ethics Committee in Gothenburg, i.e. Göteborgs Djurförsökse-
tiska Nämnd, Kammarrätten i Göteborg, Box 1531, SE401 50 Göteborg, Sweden according to
Swedish legislation. Ethical approvements and approvement dates: 277–2011 (2011-09-11) and
233–2014 (2014-12-17). According to the ethical permission the mice were sacrificed by injec-
tion of an intraperitoneal injection of ketamine/medetomidin followed by opening of thorax
and heart puncture. If the mice were affected by arthritis in the forepaws, scored higher than 5,
they were euthanized as described above, and culled. In the present experiments, no mouse
reached a score higher than 5 in the forepaws.
Lentiviral transduction and transplantation hematopoietic stem cells
Femurs from DBA/1 mice (Taconic) 7–10 weeks of age were obtained and the femurs were clean
of muscles and tendons and subsequently hematopoietic stem cells were purified using Mouse
Hematopoietic Progenitor Cell Enrichment Kit (Stemcell Technologies, Manchester, UK). Puri-
fied hematopoietic stem cells were cultivated at a concentration of 1x106 cells/ml in a 12-well
plate in StemSpan (Stemcell Technologies) overnight in the presence of 100ng/ml mSCF,
100ng/ml Flt-3L, 100ng/ml IL-11, 20ng/ml IL-3 (R&D Systems, Abingdon, UK) and lentiviral
particles at multiplicity of infection 75 (i.e. 75 lentiviral particles/cell). The cells were resuspended
in PBS the following day and subsequently injected intravenously (2.5x105 cells/mouse) into syn-
genic lethally irradiated (8.5 Gray) recipient mice. The cells were allowed to repopulate the mice
for a minimum of 10 weeks before start of the experiments (Fig 1B).
Collagen-induced arthritis
The mice were immunized with rat CII and complete Freund’s adjuvant (CFA, Sigma-Aldrich,
Sweden) and boosted at day 21 or 28 (according to standard collagen-induced arthritis proto-
col [37]). Day of booster was changed from day 21 to 28 in the experiment shown in Fig 2D
due to changes in the Swedish legislation. Arthritis severity and frequency were graded blindly
and the arthritis (defined as visible erythema and/or joint swelling) was evaluated by inspection
Antigen-Specific Tolerance in Arthritis
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of finger/toe and ankle/wrist joints. A score was assigned for each limb: 0, neither swelling nor
erythema; 1, mild swelling and/or erythema; 2, moderate swelling and erythema; and 3, marked
swelling and erythema. The total score for each mouse was calculated by adding up the scores
for each limb.
Detection of CII-protein expression on MHCII
To investigate the presentation of CII-peptide on MHCII molecules, T cell hybridomas specific
for modified CII-peptides were used. Hcq3 hybridoma (recognizes glycosylated CII aa259-
270), Hcq4 (recognizes naked CII aa259-270) and HdBr1 (recognizes hydroxylated CII aa259-
270). To ensure proper specificity of the hybridoma, 5x104 cells from each hybridoma were co-
cultured for 24h with 5x105 naïve unsorted splenocytes and stimulated with 100 ul of naked
CII-peptide, hydroxylated CII-peptide or glycosylated CII-peptide. Analysis of IL-2 levels in
supernatants was performed using sandwich ELISA (R&D Systems) and showed specific pep-
tide responses for each hybridoma (Fig 1D). The specific T cells hybridoma were then used to
investigate CII presentation on cells from peritoneal cavity, bone marrow and spleen, 12 weeks
after transplantation. Peritoneal macrophages (PEM) and bone marrow cells from femur, tibia
as well as splenocytes were harvested from unimmunized transplanted mice (n = 6/group) and
seeded in 96-well plates in triplicates at a concentration of 5x105 cells/well with either of the T
cell hydridomas in a volume of 50 ul at a concentration of 5x104 cells/well. To study the expres-
sion of the CII-peptide on B cells, splenocytes from unimmunized LNT-Ctrl (n = 3) and
LNT-CII mice (n = 3) were depleted from T cells using a pan T cell depletion kit (Dynal, Invi-
trogen) and further positively selected for CD19 positive B cells (Stem Cell Technology). The
selected CD19 negative and CD19 positive cell populations were seeded in a 96-well plate in
triplicates at a concentration of 5x105 cells/well together with 5x104 Hcq4 hybridoma T cells.
After 24h the levels of IL-2 in culture supernatants was measured by ELISA (R&D Systems).
Histological examination of inflamed joints
Histopathologic examination of the joints was performed after routine fixation, decalcification,
and paraffin embedding. Tissue sections from fore and hind paws were cut and stained with
hematoxylin–eosin. All the slides were coded and evaluated by two blinded observers. The
specimens were evaluated with regard to synovial hypertrophy, pannus formation, and carti-
lage/bone destruction. The degree of synovitis and destruction in every joint (finger/toes,
wrists/ankles, elbows, and knees) was assigned a score from 0 to 3. Occasionally one joint was
missing in the histological sections, or embedded in such a way that it was impossible to evalu-
ate the degree of synovitis and bone/cartilage destruction. Therefore, the total score per mouse
was divided by the number of joints evaluated.
Fig 1. Lentiviral constructs andmodel design (A) LNT-Ctrl; lentiviral control construct that encodes the MHC class II–
associated invariant chain peptide (CLIP) stabilizing Invariant chain (Ii) driven by the spleen focus-forming virus (SFFV)
promoter. LNT-CII; lentiviral construct that encodes the rat collagen epitope (aa259-270, GIAGFKGEQGPK) fused into Ii. LTR;
long term repeat, cPPT; central polypurine tract, WPRE; Woodchuck Post Transcriptional Element. (B) Cartoon describing the
design of the experiment. Hematopoietic stem cells (HSCs) from DBA/1 mice were transduced with lentiviral particles
injected into lethally irradiated recipient mice. CIA was induced according to standard protocol at least 10 weeks after HSC
transplantation. (C) Naïve splenocytes were stimulated with naked, hydroxylated or glycosylated peptides and co-cultured with
T cell hybridomas specific to each post-translational modification of the CII-peptide, i.e. Hcq4 recognizes the naked peptide,
HdBr1 the hydroxylated and Hcq3 the glycosylated CII-peptide. The response was measured as IL-2 production by ELISA and
performed three times. (D) IL-2 production in response to co-culture of the T cell hybridomas with bone marrow cells, peritoneal
macrophages or spleen cells from HSC transplanted mice (n = 6/group) and performed twice. (E)Co-cultures of the T cell
hybridomas with B cells (CD19+) or non-B cells (CD19-) from LNT-Ctrl and LNT-CII HSC transplanted mice (n = 3/group) and
performed twice. Statistical analysis was performed by Student’s t-test, mean±SEM.
doi:10.1371/journal.pone.0154630.g001
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CII-specific antibodies in serum
Levels of CII-specific IgG in serum, taken at indicated time points after CII immunization,
were determined by ELISA. Low binding plates (NUNC, Fisher Scientific, Gothenburg, Swe-
den) were coated with rat CII (1 μg/ml). Serum samples were diluted (1/6000, 1/18 000, 1/54
Fig 2. Development of arthritis and B cell responses in the novel model of tolerance to collagen-induced arthritis. Severity (A) as well
as incidence of arthritis (B) were determined by macroscopical examination (LNT-Ctrl n = 25 (day 0–42), n = 17 (day 43–49) LNT-CII n = 24
(day 0–42), n = 11 (day 43–49)). The experiments have been repeated five times and the graph shows the pooled results from three
experiments (C) Histopathological examination of synovitis and bone/cartilage erosivity at termination of two pooled experiments (days 42–
49). (D) Histological photos from an LNT-Ctrl and an LNT-CII mouse at day 42 after CII immunization, B = bone, C = cartilage, S = synovium.
Scale bar 100 μm. (E)Development of CII specific IgG antibodies measured by ELISA in serum at indicated time points during CIA (n = 3-6/
group). (F) Serum levels of CII-specific IgG and subclasses IgG1, IgG2a and IgG2b at days 42–49. Experiments in Fig E and F have been
performed at least twice. Statistical analysis was performed by linear regression in (A, D), logistic regression in (B) and Mann-Whitney U-test
in (C and E), mean±SEM.
doi:10.1371/journal.pone.0154630.g002
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000 and 1/162 000) and after incubation, CII-specific IgG was detected by using biotinylated
rat anti-mouse IgG, IgG1, IgG2a or IgG2b at 0.5 μg/ml (Serotec, Oxford, UK). The assay was
developed using extravidin-horseradish peroxidase (HRP) and tetramethylbenzidine substrate.
The reactions were stopped with H2SO4 and read in Spectra Max 340PC (Molecular Devices)
at 450 nm and correction at 650 nm.
Flow cytometry of B and T cells
B and T cells were analyzed by flow cytometry (FACS) for expression of activation and differ-
entiation markers. Briefly, single-cell suspensions were prepared from draining lymph nodes
and spleen. Cells were resuspended in PBS with 10% FCS, counted (Nucleocounter) and seeded
in 96-well plates. T cells were Fc blocked (clone 2.4G2 BD) before application of surface anti-
bodies CD4 (V450 clone RM4-5, BD), CD4 (PB clone RM4-5, BD), CD25 (APC clone 3C7,
BD) or CD25 (FITC, 3C7 BD) for 20 min in room temperature (RT). B cells were stained with-
out prior Fc blocking using v450-labeled B220 (BD Biosciences) and APC-labeled CD93 for 20
min in RT. Intracellular staining was performed using FoxP3 / Transcription Factor Staining
Buffer set (eBioscience) and FoxP3 (PE clone NRRF-30 eBioscience), FoxP3 (FITC, clone FJK-
16s, eBioscience) or Helios (APC Alexa Fluor 647 clone 22F6 eBioscience) for 30 min in +8C°.
Isotype controls were used as negative controls. Analysis was performed by FlowJo Software
(Tree Star Inc., Ashland, OR, USA) and gates for surface staining were set according to flouro-
chrome minus one [39].
Adoptive transfer
Fourteen weeks after transplantation of lentivirally transduced HSCs, splenic T cells (defined
as CD3+ cells), B cells (defined as both CD19+ and MHCII+) or the remaining MHC Class II+
pool (defined as CD19- and MHCII+ cells, i.e. non-B APCs) were sorted by FACS Synergy.
Briefly, single-cell suspensions were prepared in PBS with 10% FCS. APC Anti-Mouse CD3e
(eBioscience), APC-Cy7 Rat Anti-Mouse CD19 (BD Pharmingen, US) and eFlour450 Anti-
mouse MHC Class II (I-A/I-E) (eBioscience), respectively, were added to the cell suspensions.
Following 30 min incubation at 4°C, cells were sorted by FACS. 7AA-D (BD Pharmingen, US)
were added just prior sorting for exclusion of dead cells. Purity and viability of isolated cells
was around 99 (S1 Fig). Freshly isolated cell populations (1x106 T cells, 2x106 B cells and 3x105
APC cells/mouse) were adoptively transferred into naïve syngeneic recipient mice (Fig 3B–
3D). Recipient mice were administered the cells 2 days prior to CII immunization and evalu-
ated for development of arthritis as described above.
Suppression and proliferation assays
Cells from spleen were prepared as single cell suspensions. Antigen presenting cells were purified
from spleen from LNT-Ctrl mice by negative selection using Mouse Dynabeads PanT kit (Life
Technologies Ltd, Paisley, UK). CD4+ T cells were enriched using mouse CD4 negative selection
kit (Life Technologies Ltd, Paisley, UK). Cell suspension was then stained for surface expression
of CD4 (FITC, clone RM4-4, BD) and CD25 (APC clone 3C7, BD) as described earlier. T cells
were sorted into a purified CD4+CD25- T effector cell population and a CD4+CD25+ T popula-
tion using FACS Sy3200 Sorter (Sony Biotechnology, Champaign, USA). Cells were primarily
gated as lymphocytes based on size using FSC and SSC, and to ensure that cells were singlets,
cells were gated as a single cell population using FSC-A and FSC-H. Cells were then gated as
CD4+ and then CD25+ for sorting. Post sorting cells were analyzed for viability using 7-AAD
(BD Biosciences) and purity. Sorted APCs (50000), T effector (18000) and Tregs (according to
ratio) cells were seeded in DMEM (supplemented with 10% FCS, 1% 2-mercaptoethanol, 1%
Antigen-Specific Tolerance in Arthritis
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penicillin/streptomycin, here after called complete DMEM) with added anti-CD3 (azide free,
BD) at a final concentration of 0.5 μg/ml in a 96-well plate. All co-cultures were incubated for
62h at 37°C, followed by addition of 1 μl H3 thymidine (Perkin Elmer, Waltham, Massachusetts,
USA) per well. After 12h cells were harvested and proliferation rate analyzed in Betacounter
Fig 3. Adoptive transfer of T cells, B cells and APCs. (A) Design of experiment. Adoptive transfer of sorted T cells, B cells and APCs from
LNT-Ctrl (n = 5) and LNT-CII (n = 6) mice respectively were transferred into naive recipients 2 days before CII immunization. (B) Severity of arthritis
after immunization in mice receiving T cells (LNT-Ctrl n = 6, LNT-CII n = 6). (C) B cells (LNT-Ctrl n = 7, LNT-CII n = 7) or (D) APCs (LNT-Ctrl n = 6,
LNT-CII n = 4). (E)Histopathological examination of synovitis and bone/cartilage erosivity. The experiments have been performed once. Statistical
analysis was performed using linear regression for comparing development of arthritis, Mann-Whitney U-test for comparing histopathological score,
mean±SEM.
doi:10.1371/journal.pone.0154630.g003
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(1450 LSC & Luminescence Counter, MicroBeta TriLux, PerkinElmer, Inc, Bath, UK). Antigen-
specific proliferation of whole spleen was performed at at days 14 and 28 after CII immunization.
Single cells were plated in triplicates at a concentration of 5x105 /well in a 96-well plate in
DMEM (supplemented with 10% FCS, 1% 2-mercaptoethanol, 1% penicillinum/streptomycin)
and stimulated with rat CII 50 μg/ml for 72h. As a read out, IFN-γ was analyzed in the superna-
tant using a DuoSet kit (R&D).
Cell ELISA
Single cells from spleen cells and draining lymph node were plated in complete DMEM at a
concentration of 5x105 cells/well in a 96-well plate and stimulated with 50 μg/ml CII and stan-
dard culture conditions. The supernatant was harvested after 72h, frozen in -20°C degrees and
analyzed for TNF, IL-6, IL-10, TGF-β and IFN-γ using DuoSet ELISA (R&D).
qPCR array analysis
mRNA was prepared from lymph nodes from naïve mice (n = 3) and at from LNT-CII (n = 15)
and LNT-Ctrl mice (n = 19) respectively at days 0, 3, 5, 14 and 28 after CII immunization using
RNEasy Mini Kit and QIAcube (QIAGEN) with protocol RNeasy Mini Kit Cells and Tissue
with DNase Digest according to the manufacturers instruction. RNA concentration was mea-
sured using a ND-1000 Spectrophotometer (NanoDrop). cDNA synthesis was made using
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) including RNase inhibi-
tor in a Veriti 96-Well Thermal Cycler (Applied Biosystems). cDNA was run in the 384-well
microfluid card Taqman Array Mouse Immune Panel (Applied Biosystems/Life Technologies)
detecting 90 + 6 genes using a ViiA 7 Real-Time PCR System (Applied Biosystems/Life Tech-
nologies). β-actin (Actb) and GADPH (Gadph) were selected as housekeeping genes. Relative
quantification (RQ) was calculated from the sample from a naïve DBA/1 mouse.
Statistical analysis
Statistical analyses were performed using GraphPad Prism (La Jolla, CA). Statistical differences
between independent groups were calculated using the nonparametric Mann-Whitney U test
for quantitative data and Fisher’s exact test for nominal data. Logistic regression was used to
compare the development of arthritis between groups and linear regression was used to com-
pare development of severity of arthritis between treatment groups. Two way ANOVA was
used to compare cell proliferation in co-cultures of T cells in different ratios. Multivariate fac-
tor analysis (SIMCA-P+ software; Umetrics, Umeå, Sweden) was used to examine the relation
between LNT-Ctrl and LNT-CII mice (Y-variables) and the determined gene expression levels
in the qPCR array analysis (X-variables). Orthogonal projection to latent structures DAs were
implemented to examine whether tolerized mice compared with non-tolerized mice could be
discriminated based on the various X-variables examined. The quality was assessed based on
the parameters R2, that is, how well the variation of the variables is explained by the model,
and Q2, that is, how well a variable can be predicted by the model. OPLS plots in the results are
based on X-variables with variable influence on projection (VIP) values>1.3 VIP values can be
used to discriminate between important and unimportant predictors for the model. In the
OPLS analyses, the importance of each X-variable to Y is represented by column bars. Jackknif-
ing was used to calculate SEs displayed as an error bar on each column (representing the 95%
confidence interval). Univariate analyzes by student’s t-test were performed exclusively on the
X-variables Socs1, IL-10. IFNg and IL-6 to avoid mass significance. P< 0.05 =  was considered
significant. P< 0.005 , P< 0.001.
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Results
The CII-peptide is expressed in its naked form on MHCII in LNT-CII mice
To generate a tolerogenic lentiviral vector where the immunodominant CII-peptide, i.e. amino
acids of CII (259–270), is presented on MHCII Aq by APCs, we cloned the CII-peptide aa259-
270 DNA sequence into the CLIP position of the invariant chain (LNT-CII). The native CLIP
peptide was kept as in the control vector (LNT-Ctrl) (Fig 1A) [37]. To express the CII-peptide
on APCs, hematopoietic stem cells (HSC) were transduced with lentiviral particles and injected
into lethally irradiated recipient mice (Fig 1B). The mice were allowed to reconstitute their
hematopoietic cell populations for at least 10 weeks before CIA induction. After reconstitution
we determined the expression of the CII-peptide/Aq on APCs using CII specific T cell hybrid-
omas recognizing post-translational modified forms of the peptide [40]. All hybridomas were
functional and responded as expected to their respective peptide (Fig 1C), and we found that it
was predominantly the naked non-modified variant CII-peptide that was expressed in all
assessed tissues: bone marrow, spleen and on peritoneal macrophages both before (Fig 1D) and
day 28 after CII-immunization (S1 Fig). In spleens depleted of T cells both CD19 positive B
cells as well as CD19 negative cells also expressed the naked non-modified variant of the CII-
peptide (Fig 1E and S1 Fig).
Frequency and severity of arthritis are ameliorated in LNT-CII mice
The LNT-CII mice showed an almost complete resistance to develop arthritis (severity and fre-
quency), by contrast to the LNT-Ctrl mice that developed a rapidly progressing arthritis (Fig
2A and 2B). These findings were confirmed by histopathology of the joints, which showed that
only 6% of LNT-CII mice had mild signs of synovitis and erosivity, whereas>90% of LNT-Ctrl
mice developed severe synovitis, and cartilage and bone destruction (Fig 2C and 2D). Thus,
lentiviral gene therapy using LNT-CII that presents naked CII-tolerogen on APCs prevents
development of CIA.
CII-specific IgG B cell responses are down-regulated in LNT-CII mice
It is known that the B cells and their production of CII-specific antibodies are crucial for the
development of CIA [41,42]. The serum levels of CII-specific IgG antibodies, including the
subclasses IgG1, IgG2a and IgG2b, were significantly lower in LNT-CII compared to LNT-Ctrl
mice throughout the experiment (Fig 2E and 2F). This response was not due to a general effect
on total immunoglobulin levels, which were unchanged (S2 Fig). The CII-specific IgM
response was similar in both groups of mice both before and at days 29 and 47 after CII immu-
nization (S2 Fig). These findings indicate that only the T cell dependent production of antigen-
specific IgG is affected by the induced tolerance.
B cells and non-B cells mediate tolerance to arthritis in LNT-CII mice
There are three main cell types that can contribute to immunological tolerance: Treg, APCs
and B cells. To investigate the role of each of these cell population in our tolerance model, we
isolated splenic T cells, B cells and the remaining non-B cell APC pool from mice after gene
therapy (S1 Fig). The isolated cell populations were transferred into naïve syngeneic recipients
two days before CIA was induced (Fig 3A). There were no differences between the two groups
of mice in the composition and proportion of cells before transfer with respect to leukocytes,
lymphocytes, CD4+ T cells, CD4+ Foxp3+ Tregs, MHCII+CD19+ B cells or MHCII+CD19-
non-B cell APCs (S3 Fig and Table 1). The macroscopically observed development of arthritis
was significantly ameliorated after transfer of splenic B cells (Fig 3B), non-B APCs (Fig 3C) or
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T cell from LNT-CII mice (Fig 3D). However, histopathological examination showed that
transfer of B cells, but also of T cells from LNT-CII mice reduced the degree of synovitis and
cartilage and bone destruction (Fig 3E). The histopathological differences in the joints between
the groups after transfer of non-B cell APCs were not as pronounced as for the other cell types
transferred, though this could be due to the lower amount of cells transferred (Fig 3E). At the
termination of the T cells transfer experiment we analyzed the serum levels of CII-specific IgG
in total and of all subclasses and found no statistical differences between the respective groups
(S4 Fig). Thus, transfer of T cells, B cells and non-B cell APCs from LNT-CII mice suppressed
the macroscopically observed severity of CIA, which indicates that tolerance can be induced
and maintained by multiple cell types.
The suppressive Treg function is enhanced in LNT-CII mice
Induction of tolerance by T cells could potentially be attributed to Tregs [43–45]. We assessed
the proportion of Tregs (CD4+Foxp3+ cells) at days 0, 3, 5, 28 and 49 after CIA induction. The
proportion of Tregs in the spleen and lymph nodes was increased at day 3 in LNT-CII com-
pared to LNT-Ctrl (Table 1). However, at day 5 the proportions of Tregs were reduced in
LNT-CII compared to those in LNT-Ctrl mice (Table 1, gating strategy S5 Fig). This suggests
that events crucial for tolerance take place very early after immunization with CII. To investi-
gate whether the suppressive function of Tregs was enhanced in LNT-CII mice, we purified T
effector cells (CD4+CD25-) from LNT-Ctrl and Tregs (CD4+CD25+) from immunized
LNT-CII and LNT-Ctrl mice (S6 Fig). Stimulation with anti-CD3 antibodies showed that
Tregs from LNT-CII but not LNT-Ctrl mice significantly reduced the proliferative response of
the T effector cells (Fig 4A). Unexpectedly, unsorted spleen cultures (characterized in S7 Fig
and S8 Fig) from LNT-CII mice stimulated with CII showed a tendency to increased IFN-γ
production at day 14 compared to LNT-Ctrl mice (Fig 4B). Taken together, this suggests that
Tregs from LNT-CII mice are an important mediator of the tolerogenic phenotype.
LNT-CII has limited effect on cytokine levels
Pathogenesis of CIA is characterized by a Th1 and Th17 response that is counter-acted by reg-
ulatory cytokines such as IL-10, IL-4 and TGF-β [46,47]. To analyze the cytokine pattern dur-
ing the course of CIA mRNA levels of TNF-α, IFN-γ, IL-4 and IL-17A in draining lymph
nodes were determined. In addition, protein levels of TNF-α, IFN-γ, IL-6, IL-10 and TGF-β in
serum as well as draining lymph node cultures at day 49 after immunization were assessed.
Despite the significant differences in arthritis outcome, there were no differences between the
groups in the levels of any of these mRNA or proteins except IFN-γ, which was decreased in
Table 1. Proportion of CD4+Foxp3+ Tregs of CD4+ cells in spleen and draining lymph nodes before and after immunization.
Tissue Mice Day
0 3 5 28 49
Spleen LNT-Ctrl 26.1 ± 0.6 22.6 ± 0.6 25.9 ± 0.2 28.0 ± 1.2 21.5 ± 1.6
Spleen LNT-CII 25.5 ± 1.8 26.1 ± 0.2** 24.2 ± 0.3* 24.1 ± 1.0* 21.1 ± 1.2
Lymph nodes LNT-Ctrl 11.8 ± 0.9 12.0 ± 0.8 12.6 ± 0.7 ND ND
Lymph nodes LNT-CII 12.37 ± 0.4 14.9 ± 0.6* 11.7 ± 0.9 ND ND
*p<0.05 and
**p<0.01 LNT-Ctrl vs LNT-CII. Data presented as mean ± SEM. At day 0, 3, 5 and 28 n = 3, at day 49 n = 5–6 per group. ND; not done.
doi:10.1371/journal.pone.0154630.t001
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lymph node cultures from LNT-CII (mean ± SEM pg /ml; 22.1 ± 3.86) compared to LNT-Ctrl
(50.08 ± 8.8, p = 0.03).
Early increase in Socs1 expression levels is associated with tolerance
As it proved difficult to explain the tolerant phenotype by one single factor at a certain time
point, an immune card array that detects mRNA levels of 90 different genes was employed on
draining lymph nodes 0, 3, 5, 7, 14 and 28 days after CII immunization. Multivariate
Fig 4. Involvement of T cells in tolerance induction. (A) Capacity of Tregs cells to down-regulate effector
T cell responses. Sorted Tregs cells from LNT-Ctrl or LNT-CII mice were co-cultured with LNT-Ctrl T effector
cells in ratios 1:1, 1:5 and 1:10 for three days and proliferation measured by radioactive thymidine
incorporation (counts per minutes). Y-axis—percentage of proliferation compared to the negative control
containing sorted T effector cells only (n = 6/group). The experiment has been repeated three times. (B) CII-
specific IFN-γ production from stimulated spleen cells obtained 14 days after CII immunization, n = 4–5 and
repeated once. Statistical analysis was performed using Two-way ANOVA for evaluation of proliferative
responses in (A) and Mann-Whitney U-test in (B), mean±SEM.
doi:10.1371/journal.pone.0154630.g004
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discriminant analysis, OPLS-DA, indicates that the gene expression profile is different in
LNT-CII vs LNT-Ctrl mice at all time points (Fig 5A and S9 Fig). The variables that displayed
the strongest association (positive or negative) with either group of mice are identified in the
column plots (Fig 5B and S9 Fig). Variables with a positive bar are positively associated with
LNT-CII mice whereas variables with bars in the opposite direction are inversely related to the
LNT-CII mice.
At day 3 after CII immunization the OPLS-DA analysis showed that the mRNA expression
of Socs1 along with Il10 associated strongly with LNT-CII mice, while Ifng associated with
LNT-Ctrl mice (Fig 5B). The individual values of mRNA expression of Socs1, Il10, Ifng and Il6
during the course of arthritis are plotted in Fig 5C–5F. Day 3 after CII immunization is also the
only time point where the proportion of Tregs was increased in tolerized LNT-CII mice
(Table 1). Thus, the early increase in Socs1mRNA coincides with the increased frequency of
Tregs and resistance to arthritis development.
Discussion
In this study we demonstrate that transfer of hematopoietic stem cells expressing the CII-pep-
tide on MHCII Aq (LNT-CII) to lethally irradiated mice induces an almost complete antigen-
specific tolerance CIA. We show that only 5% of the CII-tolerized mice developed a mild syno-
vitis while more than 95% of control mice developed a severe synovitis as well as severe carti-
lage and bone destruction. We found that early events including up-regulation of SOCS1 and
an increased proportion of Tregs associated with resistance to arthritis development. We dem-
onstrate that the tolerance to CIA caused by excessive presentation of the CII-tolerogen on
APCs is a process with multiple immunological effector mechanisms, as transfer of both T
cells, B cells and to some extent also MHCII+ cells from CII-tolerized mice to naïve recipients
ameliorate the course and severity of arthritis. Further, the OPLS-DA analyses of mRNA
expression from peripheral lymph nodes clearly shows that tolerance mechanisms differ sub-
stantially between CII-tolerized and control mice but also between different time points
throughout the course of CIA.
It is well known that Tregs are generated both in the thymus and in peripheral tissues [48]
and that functional Tregs cells are pivotal to maintain immunological homeostasis [49]. We
demonstrate that early after CII immunization (day 3) there is an increased proportion of
Tregs and up-regulation of the mRNA expression of SOCS1 and IL-10 in tolerant LNT-CII
mice. At the same time, LNT-CII mice also down-regulate mRNA expression of IFN-γ and to
some extent IL-6. IL-10 is a known inducer of SOCS1 [50], and we have previously shown that
the CIA is alleviated in the presence of an increased IL-10 production, which coincided with an
increased SOCS1 expression in draining lymph nodes and reduced serum levels of IL-6 [34].
SOCS1 prevents JAK/STAT signaling, and plays an important role in Tregs by maintaining
Foxp3 expression and by suppressing IFN-γ and IL-17 production [51]. Thus, we hypothesize
that tolerance is established very early after CII immunization, and that it involves both genera-
tion of Tregs as well as SOCS1 that shuts down the CII-specific effector response. This hypoth-
esis is further supported by clinical studies showing that tolerance induction is more successful
if the host’s immune system has a tolerogenic phenotype [52].
We also found that suppressive capacity of Tregs from tolerant LNT-CII mice was preserved
after general stimulation with anti-CD3, while the suppressive capacity of LNT-Ctrl Tregs was
decreased. This may be due to the inflammatory status in these animals, since it has been
shown that in RA the Tregs are under the influence of the cytokine milieu and that this has a
negative effect on their suppressive function, e.g. anti-TNF treatment has been shown to
improve Treg function [53]. Another explanation could be that the proportion of antigen
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Fig 5. qPCR array and SOCS1 association with LNT-Ctrl vs LNT-CII at day 3 after CII immunization. (A)OPLS-DA scatter dot plot showing the
separation of gene expression in tolerized or non-tolerized mice and (B)OPLS-DA column loading plot that depicts the association between LNT-CII and
LNT-Ctrl mice with the expression of different genes. X-variables represented with a positive bar are positively associated with LNT-CII mice, whereas
variables in the opposite direction are inversely related to this group of mice. The larger the bar and smaller the error bar, the stronger and more certain is
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(CII)-specific Tregs and T effector cells in LNT-CII is altered compared to LNT-Ctrl mice. It is
likely that both an increased induction of antigen (CII)-specific Tregs as well as fewer antigen
(CII)-specific T effector cells operate in LNT-CII mice as the CII-peptide is presented on both
B cells and non-B cell APCs.
Earlier studies have highlighted that post-translational glycosylation of the CII-epitope is
important for arthritis development in the CIA model [54]. Further, CII-autoreactive T cells
that recognize the glycosylated CII-epitope have been found in blood and synovial fluids from
patients with RA, and there is a significant correlation between disease activity and T cell
response to the glycosylated CII-epitope [55]. It has also previously been shown that overex-
pression of the glycosylated CII-epitope is superior to the naked epitope in tolerance induction
to CIA [14]. We show that it is the naked rather than the glycosylated CII-peptide that is pre-
sented, which can be due to difficulties for the APC to glycosylated the CII-peptide in our
experimental system. Nevertheless, overexpression of the naked CII-peptide induces tolerance
to CIA [37,38], though it is possible that the tolerogenic effect might have been even better if
the glycosylated CII-peptide was expressed. The discrepancies between the findings regarding
the tolerogenic effects of glycosylated and naked CII-peptide may be explained by yet unpub-
lished work showing that it is the non-modified naked CII peptide that is presented in thymus
(personal communication, J Bäckström, KI). This implies that central tolerance mechanisms
are important and it would in future studies be very interesting to perform thymectomy prior
to irradiation, repopulation and induction of arthritis to further decipher the puzzle of toler-
ance. Also supporting a role for central tolerance in autoimmune arthritis is the fact that aber-
rant ZAP-70, a key signal transduction molecule in T cells during thymic selection changes the
thresholds of T cells to thymic selection, leading to the positive selection of otherwise nega-
tively selected autoimmune T cells and to subsequent development of chronic autoimmune
arthritis in mice [56].
Intravenous administration of lentiviral particles encoding LNT-CII/LNT-Ctrl either before
or after CII immunization induces partial tolerance to CIA [37,38], while transplantation of
lentivirally transduced HSCs induces an almost complete tolerance. The main reasons in effi-
cacy between the two delivery systems are most likely the amount of time between transfer of
lentiviral particles and CII immunization, and the impact as well as the amount of the CII-pep-
tide expression in the mouse. After transfer of transduced HSCs, the immune system was
allowed to repopulated for> 10 weeks, while the lentiviral particles were injected either 30
days before or, at different time points after CII-immunization. Transfer of transduced HSCs
to a lethally irradiated mouse leads to differences in function, but not in proportions, of
immune cells already before CII-immunization (Fig 5 and S9 Fig). It is also well known that
presentation of a high amount of antigen without co-simulation leads to tolerance. The expres-
sion of the CII-peptide was detectable with the T cell hybridomas after transfer of lentiviral
transduced HSCs (Fig 1D), but not after intravenous injection that indicates that there is a
lower presentation of the peptide.
B cells are potent professional APCs that have been previously implicated in tolerance
induction and disease development [27,57,58]. The B cells contribute to CIA both by present-
ing antigens and by producing cytokines and CII-specific antibodies [59]. In the tolerogenic
LNT-CII mice, there is a profound reduction of the B cell response, and as this require T cell
activation, these data support an increased suppression by Tregs and a reduction in antigen-
the contribution to the model. The final OPLS-DA loading plots are based on parameters with VIP values1.3. R2Y indicates how well the variation of Y
is explained, whereas Q2 indicates how well Y can be predicted. Univariate analysis (Student’s t-test) of (C) SOCS1 (D) of IL-10 (E) IFN-γ (F) IL-6,
n = 2–4 animals/group, mean ± SEM. Actb andGadphwere selected as housekeeping genes and relative quantification was calculated from the sample
of a naïve DBA/1 mouse.
doi:10.1371/journal.pone.0154630.g005
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specific T effector cells. Further, self-antigen expression by B cells has been shown to be very
efficient in inducing Tregs in the periphery, whereas self-antigen expression by DC led mainly
to deletion and anergy of antigen-specific T effector cells [24].
From day 5 and onwards after CII immunization we could not detect a general increase in
the proportion of Tregs in the tolerant LNT-CII mice, but rather the opposite as the proportion
of Tregs increased in the arthritic LNT-Ctrl mice. This could be explained by the absence of an
ongoing immune response in LNT-CII mice, while the arthritic LNT-Ctrl mice need to mobi-
lize their Tregs to limit the ongoing inflammation, as it is well known that Tregs increase dur-
ing inflammation [60].
The kinetics of IFN-γ in the LNT-CII mice is interesting. The levels are decreased compared
to LNT-Ctrl mice at day 3, increased at day 14, similar at day 28 and decreased at day 49 after
CII immunization. This most likely mirrors that there are different effector mechanisms gov-
erning the tolerogenic state at different time points. IFN-γ has both regulatory and immune
stimulating properties. It can inhibit osteoclastogenesis and formation Th17 cells, as well as
facilitate the induction and increase the suppressive capacity of Tregs, and in addition up regu-
late MHCII as well CD80/86 expression (reviewed in [61]). IFN-γ is also of importance for B
cell responses and IFN-γ production by T follicular helper cells is necessary for germinal centre
formation and the production of high affinity antibodies [62].
Regulatory B cells can also influence the inflammatory response [63]. Regulatory B cells are
defined either by IL-10 production or by surface markers including for B220/CD23/CD24/
IgM/CD1d [58], however our data (not shown) do not support an increased B regulatory cell
compartment. Thus, the reduced B cell response in tolerant LNT-CII mice is most likely sec-
ondary to lack of a CII-specific T cell response.
To summarize, we have shown that a sustainable tolerance against CIA can be established
by endogenous expression of naked unglycosylated CII-peptide on MCHII. Tolerance is estab-
lished very early during the course of arthritis and can be mediated by both B and non-B cells
as antigen presenting cells. We suggest that the model we have established using lentiviral con-
structs can be used to elucidate the detailed functions of not only tolerogenic states in CIA, but
also in other experimental autoimmune models.
Supporting Information
S1 Fig. Gating strategy, purity and viability of cells used in CII-peptide presentation assay
and adoptive transfer and CII-peptide expression. (A) Detection of the CII-peptide in sple-
nocytes by T cell specific hybridomas at day 28 after transfer of lentivirally transduced HSCs.
(B) Verification of the functionality of the hybridomas. (C) Purity of non-B cells APCs and B
cells used for the experiment in Fig 1E. (D) FACS sorting of B cells and T cells was initiated
through gating for BSC area vs FALS area followed by gating for 7-AAD. T cell sorting was per-
formed by gating for CD3+ or CD19- cells. Sorting of B cells was performed gating for MHCII
positive CD19+ cells and sorting non B cell APCs gating for MHCII+ CD19- cells. (E) Flow
cytometry using BSC area (y-axis) vs 7-AAD (x-axis) to estimate cell viability and purity of the
sorted cells using MHCII (y-axis) vs CD19 (x-axis) for B cells and CD3 (y-axis) vs CD19 (x-
axis) for T cells.
(EPS)
S2 Fig. Serum levels of general IgG and CII-specific IgM. (A) Serum levels of general IgG at
day 49 after CII immunization, n = 7+6 mice. (B) Serum levels of CII-specific IgM antibodies
at day 0, 27 and 49 after CII immunization, n = 6+6 mice.Goat anti-mouse polyclonal IgG anti-
bodies (Jackson Immunology Research, Suffolk, England) was used as coating, and 2% BSA
(Sigma-Aldrich) for blocking. Serum samples were serially diluted from 1/ 7500 to 1/202 500)
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The total IgG levels in serum was detected by a biotinylated goat anti-mouse IgG (Southern
Biotechnology, Alabama, USA) or biotinylated (Fab)2 goat antimouse IgM (Jackson Immu-
noResearch Laboratories). The assays were developed using extravidin-horseradish peroxidase
(HRP) and tetramethylbenzidine substrate. The reactions were stopped with H2SO4 and read
in Spectra Max 340PC (Molecular Devices) at 450 nm and correction at 650 nm. Data were
expressed as optical density (OD).
(EPS)
S3 Fig. Cell population before and after CII immunization. (A) The absolute number of leu-
kocytes and lymphocytes in blood before CII immunization, n = 6+7 mice were counted in a
Sysmex Cell counter. The distribution of (B) CD4+, CD19+MHC II+ and CD19-MHC II+ cells
in blood before CII immunization, (C) lymph nodes and (D) bone marrow. (E) Intracellular
expression of Foxp3 and CTLA in CD4+CD25+ T cells from lymph nodes before CII immuni-
zation, n = 3+4 mice. (F) Expression level (MFI) of CD62L on CD4+ cells in blood (G)MFI of
MHCII on CD19+ and (H) CD19- cells in blood before and during the course of arthritis, each
mouse is shown as individual dots. The cells were stained for flow cytometry as previously
described.
(EPS)
S4 Fig. Serum levels of CII-specific IgG after adoptive transfer of T cells, day 39 after CII
immunization. The different subclasses of IgG as well of CII-specific total IgG are indicated,
n = 6+6 mice.
(EPS)
S5 Fig. Gating strategies and phenotype of Tregs.
(EPS)
S6 Fig. Phenotypes of cells in the T cell suppression experiments. (A-B) Gating strategy and
purity of CD4+CD25+ T cells in the T cell suppression assay (Fig 4A). (C) Purity of T cell
depleted antigen presenting splenocytes used in the T cell suppression assay (Fig 4A).
(EPS)
S7 Fig. Phenotype of B cells and non-B cell APC at day 14 after CII-immunization. The fol-
lowing antibodies for flow cytometry CD21-Fitc, CD23-PE-Cy7, CD93-APC, CD19-V450,
IgD-bio/PerCP and MHCII-PE were used.
(EPS)
S8 Fig. Phenotype of CD4 positive T cells in spleen at days 14 and 28 after CII-immuniza-
tion.
(EPS)
S9 Fig. qPCR array and SOCS1 association with LNT-Ctrl vs LNT-CII at days 0, 5, 14 and
28 after CII immunization. (A, C, E, G) OPLS-DA scatter dot plot showing the separation of
gene expression in tolerized or non-tolerized mice. (B, D, F, H) show the OPLS-DA column
loading plot that depicts the association between LNT-CII and LNT-Ctrl mice with the expres-
sion of different genes. X-variables represented with a positive bar are positively associated
with LNT-CII mice, whereas variables in the opposite direction are inversely related to this
group of mice. The OPLS-DA column plots are based on variables with VIP values1.3. R2Y
indicates how well the variation of Y is explained, whereas Q2 indicates how well Y can be pre-
dicted.
(EPS)
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